Skip to main content

Talk Bio

Search This Blog

BIO board met with national security, health officials on China’s biotech rise, CEO says (June 2026 news digestable summary)

on June 26, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

The Biotechnology Innovation Organization (BIO) board met with U.S. national security and health officials to discuss how China’s rapid rise in biotechnology is reshaping the global industry landscape.

BIO CEO John Crowley told investors on June 23, 2026 that the board was briefed by federal officials on China’s biotech ambitions and that crafting a China strategy is now a top priority for the trade group.

Current U.S.–China tensions over biotech include concerns about American dependence on Chinese biomanufacturing, data flows, and clinical trial infrastructure, as well as the broader risk of China achieving dominance in global biotechnology.

Sources:

BIO board spoke with national security, health officials on ...

National Security - Biotechnology Innovation Organization | BIO

BIO Separates from China's WuXi AppTec Amid National ...

BIO CEO hails congressional report on threat of China dominating ...

BIO expert: Future of biotech depends on China competition

BIO CEO John Crowley tells Senate how to support biotech

Gallagher Issues Statement on Biotechnology Innovation Organization Endorsement of BIOSECURE Act, Removal of WuXi AppTec from Org

WuXi Biologics withdraws from 2024 BIO convention amid worsening geopolitical tensions

Biotechnology is a national security Imperative, says BIO CEO

BIO 2026: US needs to dodge China's 'inescapable dependencies ...

Ep. 56 - BIO’s John Crowley on the Biosecure Act

BIO Board member testifies on China's clinical trial ...

US National Security, China and Biotechnology in 2024 - BioSpace

BIO changes stance, backs bill to limit China’s role in US biotech

BIO board biomanufacturing Biosecure Act China Clinical Trials emotional dependency health officials National Security risedronate threat

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Powered by Blogger

X-Data LLC